HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $400
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio maintains a Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $395 to $400.
May 07, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals' price target was raised from $395 to $400 by HC Wainwright & Co., maintaining a Buy rating.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This endorsement could lead to increased investor confidence and a short-term uplift in ALNY's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100